Clinical Trial Update: To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 trial of avosentan for diabetic nephropathy was terminated; the update does not provide results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• Avosentan (avosentan)

Snippet

Sponsor: Speedel Pharma Ltd. | Conditions: Diabetic Nephropathy | Phase 3 | Status: TERMINATED